No headlines found.
Business Wire (Tue, 23-Dec 8:05 AM ET)
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Globe Newswire (Fri, 12-Dec 10:31 AM ET)
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
Business Wire (Wed, 19-Nov 4:01 PM ET)
Business Wire (Tue, 18-Nov 8:41 AM ET)
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
Business Wire (Mon, 10-Nov 7:30 AM ET)
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
Business Wire (Wed, 5-Nov 1:47 PM ET)
Business Wire (Fri, 17-Oct 8:00 AM ET)
Business Wire (Thu, 16-Oct 7:48 AM ET)
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Agenus trades on the NASDAQ stock market under the symbol AGEN.
As of December 24, 2025, AGEN stock price climbed to $3.35 with 375,630 million shares trading.
AGEN has a beta of 2.00, meaning it tends to be more sensitive to market movements. AGEN has a correlation of 0.12 to the broad based SPY ETF.
AGEN has a market cap of $113.93 million. This is considered a Micro Cap stock.
Last quarter Agenus reported $30 million in Revenue and $1.94 earnings per share. This fell short of revenue expectation by $-61 million and missed earnings estimates by -$.30.
In the last 3 years, AGEN traded as high as $61.39 and as low as $1.38.
The top ETF exchange traded funds that AGEN belongs to (by Net Assets): VTI, VXF, IWC, MSSM.
AGEN has outperformed the market in the last year with a return of +23.2%, while the SPY ETF gained +17.3%. However, in the most recent history, AGEN shares have underperformed the stock market with its stock returning -24.5% in the last 3 month period and -14.5% for the last 2 week period, while SPY has returned +4.4% and +1.4%, respectively.
AGEN support price is $3.16 and resistance is $3.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGEN shares will trade within this expected range on the day.
